spacer
home > pmps > autumn 2003 > cryogenics leads the way in emissions control
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Cryogenics Leads the Way in Emissions Control

Emissions control has long been an important management issue for pharmaceutical manufacturers in Europe and beyond, but emerging legislation implemented throughout EU member states is forcing the industry to take a closer look at abatement technologies in search of solutions which will ensure compliance not just now, but in the future too.

Legislation puts Focus on Solvent Recovery

The manufacture of pharmaceutical products is reliant on a number of organic solvents, producing emissions in a number of process areas - from reactor vents to storage tanks and vacuum pumps. Dichloromethane, methanol, ethyl acetate, acetone, toluene, xylene, triethylamine, tetrahydrofurane, butyl acetate and isopropanol are among the VOCs regularly used by pharmaceutical manufacturers and legislation is limiting these emissions year on year. Industrial emissions to the atmosphere first became a focus of environmental regulation with the introduction of the Clean Air Act in 1993. Since then increasing concern about the effect of air pollutants on the environment has led to the development of the UK's National Air Quality Strategy, setting targets which are to be achieved by 2005.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Diana Raine, Business Manager for Cryogenics in Europe at Air Products

Diana Raine is Air Products' Business Manager for cryogenics in Europe and specialises in finding applications for cryogenic technology in modern industrial processes. She joined the company 12 years ago with a Masters in Chemical Engineering.

spacer
Diana Raine
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research

Philadelphia and London – June 10, 2019: CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health (signanthealth.com). Uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite, Signant makes it easier to participate in – and sites and study teams to run – clinical trials. This intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable sponsors and CROs to extend the reach of drug development, expand patient opportunities and improve data quality.
More info >>

White Papers

The Power of Execution in Clinical Research

Medpace

Medpace, long known for its excellence in conducting Phase I-IV studies on a global platform, is particularly noted for its therapeutic excellence. When that expertise is combined with operational precision, the results are nothing short of stellar. The Medpace full-service outsourcing approach – combined with therapeutic expertise, regulatory know how, and global presence – delivers clinical studies with an industry recognized track record.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement